Lotilaner ophthalmic solution reduces risk of worsening Demodex blepharitis symptoms

Lotilaner ophthalmic solution, 0.25%, is significantly more effective than a placebo in treating Demodex blepharitis (DB), as it is more likely to prevent worsening of symptoms or even improve them over a 6-week treatment period, according to a poster presented at the 2024 Women in Ophthalmology Summer Symposium.

A post-hoc analysis of the Saturn-1 and Saturn-2 clinical trials reaffirmed the efficacy of lotilaner ophthalmic solution, 0.25%, in treating DB. The randomized, double-masked, vehicle-controlled studies originally demonstrated the safety and effectiveness of a 6-week, twice-daily regimen of lotilaner drops for DB. In this analysis, researchers assessed the progression of DB symptoms in patients over the treatment period, comparing those treated with lotilaner to those given a placebo vehicle.

Results indicated that patients receiving the vehicle were significantly more likely to see no improvement or a worsening of symptoms, with 42% and 68% of patients experiencing unchanged or increased severity in collarettes and erythema, respectively, by day 43. In contrast, only 5% of patients treated with lotilaner showed no improvement or worsening in collarette severity, and 51% in erythema severity, highlighting the superior effectiveness of lotilaner in managing the symptoms of DB.

Reference
Rapoport Y. Worsening or no improvement in Demodex blepharitis in patients receiving vehicle control vs. lotilaner ophthalmic solution, 0.25%. Poster presented at: WIO 2024.